Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs
- PMID: 22492884
- DOI: 10.1377/hlthaff.2011.1301
Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs
Abstract
Generous coverage of specialty drugs for cancer and other diseases may be valuable not only for sick patients currently using these drugs, but also for healthy people who recognize the potential need for them in the future. This study estimated how healthy people value insurance coverage of specialty drugs, defined as high-cost drugs that treat cancer and other serious health conditions like multiple sclerosis, by quantifying willingness to pay via a survey. US adults were estimated to be willing to pay an extra $12.94 on average in insurance premiums per month for generous specialty-drug coverage--in effect, $2.58 for every dollar in out-of-pocket costs that they would expect to pay with a less generous insurance plan. Given the value that people assign to generous coverage of specialty drugs, having high cost sharing on these drugs seemingly runs contrary to what people value in their health insurance.
Similar articles
-
Impact of cost sharing on prescription drugs used by Medicare beneficiaries.Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003. Epub 2010 May 7. Res Social Adm Pharm. 2010. PMID: 20511109
-
Comparing employer-sponsored and federal exchange plans: wide variations in cost sharing for prescription drugs.Health Aff (Millwood). 2015 Mar;34(3):467-76. doi: 10.1377/hlthaff.2014.0615. Health Aff (Millwood). 2015. PMID: 25732498
-
Limited options to manage specialty drug spending.Res Brief. 2012 Apr;(22):1-13. Res Brief. 2012. PMID: 23155549
-
Introduction to value-based insurance design.J Am Coll Radiol. 2008 Nov;5(11):1118-24. doi: 10.1016/j.jacr.2008.06.014. J Am Coll Radiol. 2008. PMID: 18954811 Review.
-
Insurance coverage of male infertility: what should the standard be?Transl Androl Urol. 2018 Jul;7(Suppl 3):S310-S316. doi: 10.21037/tau.2018.04.25. Transl Androl Urol. 2018. PMID: 30159237 Free PMC article. Review.
Cited by
-
The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.J Med Internet Res. 2018 Oct 30;20(10):e11168. doi: 10.2196/11168. J Med Internet Res. 2018. PMID: 30377144 Free PMC article.
-
Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics.Pharmacoeconomics. 2017 Aug;35(8):793-804. doi: 10.1007/s40273-017-0511-7. Pharmacoeconomics. 2017. PMID: 28455834 Free PMC article. Review.
-
National Survey Indicates that Individual Vaccination Decisions Respond Positively to Community Vaccination Rates.PLoS One. 2016 Nov 21;11(11):e0166858. doi: 10.1371/journal.pone.0166858. eCollection 2016. PLoS One. 2016. PMID: 27870907 Free PMC article.
-
Measuring the Value of Pharmaceuticals in the US Health System.Pharmacoeconomics. 2017 Jan;35(1):1-4. doi: 10.1007/s40273-016-0463-3. Pharmacoeconomics. 2017. PMID: 27785770 Free PMC article. No abstract available.
-
Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study.Pharmacoeconomics. 2016 Dec;34(12):1255-1265. doi: 10.1007/s40273-016-0435-7. Pharmacoeconomics. 2016. PMID: 27461538
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
